As a member of the PCBP family proteins, PCBP1 is reported to be reduced in lung cancer, cervical cancer, breast cancer, colon cancer, and liver cancer [24–27], suggesting that altering PCBP1 expression may become a possible therapeutic strategy. Here, PCBP1 is linked to malignant colon neoplasm.